Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169


Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.

Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T.

Target Oncol. 2017 Oct;12(5):571-597. doi: 10.1007/s11523-017-0514-5.


Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.

Ciuleanu TE, Ahmed S, Kim JH, Mezger J, Park K, Thomas M, Chen J, Poondru S, VanTornout JM, Whitcomb D, Blackhall F.

Br J Cancer. 2017 Sep 5;117(6):757-766. doi: 10.1038/bjc.2017.226. Epub 2017 Aug 3.


Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ.

Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10.


Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.

Wang YT, Pan SH, Tsai CF, Kuo TC, Hsu YL, Yen HY, Choong WK, Wu HY, Liao YC, Hong TM, Sung TY, Yang PC, Chen YJ.

Sci Rep. 2017 Mar 14;7:44021. doi: 10.1038/srep44021.


Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer.

Azad AK, Lawen A, Keith JM.

PLoS One. 2017 Mar 13;12(3):e0173331. doi: 10.1371/journal.pone.0173331. eCollection 2017.


Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):27-35. doi: 10.1016/j.jtho.2016.09.003. Epub 2016 Sep 15. Review.


EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy.

Chang H, Oh J, Zhang X, Kim YJ, Lee JH, Lee CT, Chung JH, Lee JS.

Onco Targets Ther. 2016 Aug 19;9:5153-62. doi: 10.2147/OTT.S107291. eCollection 2016.


A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.

Gomez-Roman N, Stevenson K, Gilmour L, Hamilton G, Chalmers AJ.

Neuro Oncol. 2017 Feb 1;19(2):229-241. doi: 10.1093/neuonc/now164.


Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging.

Fecher D, Hofmann E, Buck A, Bundschuh R, Nietzer S, Dandekar G, Walles T, Walles H, Lückerath K, Steinke M.

PLoS One. 2016 Aug 8;11(8):e0160282. doi: 10.1371/journal.pone.0160282. eCollection 2016.


Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.

Frago S, Nicholls RD, Strickland M, Hughes J, Williams C, Garner L, Surakhy M, Maclean R, Rezgui D, Prince SN, Zaccheo OJ, Ebner D, Sanegre S, Yu S, Buffa FM, Crump MP, Hassan AB.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):E2766-75. doi: 10.1073/pnas.1513023113. Epub 2016 May 2.


XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.

Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, Weinzierl T, Rieder N, Bacac M, Ries CH, Kettenberger H, Schlothauer T, Friess T, Umana P, Klein C.

MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16.


Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Park JH, Choi YJ, Kim SY, Lee JE, Sung KJ, Park S, Kim WS, Song JS, Choi CM, Sung YH, Rho JK, Lee JC.

Oncotarget. 2016 Apr 19;7(16):22005-15. doi: 10.18632/oncotarget.8013.


miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.

Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X, Peng L, Sun J, Chen Z.

Int J Oncol. 2016 May;48(5):1855-67. doi: 10.3892/ijo.2016.3401. Epub 2016 Feb 19.


BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.

Franks SE, Jones RA, Briah R, Murray P, Moorehead RA.

BMC Res Notes. 2016 Mar 1;9:134. doi: 10.1186/s13104-016-1919-4.


Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.

Kim N, Cho A, Watanabe H, Choi YL, Aziz M, Kassner M, Joung JG, Park AK, Francis JM, Bae JS, Ahn SM, Kim KM, Park JO, Park WY, Ahn MJ, Park K, Koo J, Yin HH, Cho J.

Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318.


Cellular and molecular aspects of pancreatic cancer.

Gharibi A, Adamian Y, Kelber JA.

Acta Histochem. 2016 Apr;118(3):305-16. doi: 10.1016/j.acthis.2016.01.009. Epub 2016 Feb 8. Review.


Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.

Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T.

Cancer Sci. 2016 Apr;107(4):461-8. doi: 10.1111/cas.12905. Epub 2016 Mar 28.


ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB.

PLoS One. 2016 Jan 20;11(1):e0147344. doi: 10.1371/journal.pone.0147344. eCollection 2016.


ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.

Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, Hotta N, Shimada Y, Isomura H, Suzuki M, Fujimoto T, Takahashi T.

Nat Commun. 2016 Jan 4;7:10060. doi: 10.1038/ncomms10060.

Supplemental Content

Support Center